Eli Lilly, Amgen Sue HHS for Unlawful Certifications of Drug Discount Program Recipients
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Market Closed -
Other stock markets
|
Pre-market 08:57:59 am | |||
293.54 USD | -1.42% |
|
296.76 | +1.10% |
02:26am | Hansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator | MT |
Feb. 06 | Daiwa Securities Adjusts Amgen's Price Target to $350 From $360 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration